TRGC1 and neoplasm: Markers included CD4+ (helper T cells), CD8+ (cytotoxic T cells), CD11c+ (dendritic cells), TCRγ/δ+ (γ/δ T cells), ATRX+ (tumour cells) and DAPI+ (nuclei), with STING as a primary marker of interest.